JP2004538308A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538308A5
JP2004538308A5 JP2003516533A JP2003516533A JP2004538308A5 JP 2004538308 A5 JP2004538308 A5 JP 2004538308A5 JP 2003516533 A JP2003516533 A JP 2003516533A JP 2003516533 A JP2003516533 A JP 2003516533A JP 2004538308 A5 JP2004538308 A5 JP 2004538308A5
Authority
JP
Japan
Prior art keywords
composition
phosphate
weight
total composition
electron transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003516533A
Other languages
English (en)
Other versions
JP4745608B2 (ja
JP2004538308A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2002/001003 external-priority patent/WO2003011303A1/en
Publication of JP2004538308A publication Critical patent/JP2004538308A/ja
Publication of JP2004538308A5 publication Critical patent/JP2004538308A5/ja
Application granted granted Critical
Publication of JP4745608B2 publication Critical patent/JP4745608B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (20)

  1. 皮膚の症候を予防し、緩和し、又は皮膚の状態を処置するための化粧用又は医薬用組成物であって、有効な皮膚浸透量の、1又は複数の電子伝達剤の1又は複数のリン酸誘導体の1又は複数の錯体を含んで成る化粧用又は医薬用組成物
  2. 局所的に許容される担体を更に含んで成る、請求項1に記載の組成物
  3. 皮膚の症候を予防し、緩和し、又は皮膚の恒常性の悪化、炎症、紅斑、創傷、火傷、日光感受性、ふけ、酒さ、皮膚炎、歯肉炎、日焼け、熱傷、乾癬、虫刺され、脂漏性皮膚炎、皮膚肥厚、角膜炎、湿疹、光による老化、皺、尋常性疣贅、足底疣贅、表皮層の肥厚及び色素沈着から成る群から選択される皮膚の状態を処置するために使用される場合の、請求項1に記載の組成物
  4. 有効な皮膚浸透量が全組成物の重量当たり0.01〜30%である、請求項1に記載の組成物
  5. 有効な皮膚浸透量が全組成物の重量当たり1〜15%である、請求項4に記載の組成物
  6. 有効な皮膚浸透量が全組成物の重量当たり1〜3%である、請求項5に記載の組成物。
  7. 1又は複数の電子伝達剤の1又は複数のリン酸誘導体の1又は複数の錯体における電子伝達剤が、鏡像体及びラセミ体のアルファ、ベータ及びガンマのトコール及びトコトリエノールを含むヒドロキシクロマン;ビタミンK1及びユビキノンの還元型のキノール;レチノールを含むヒドロキシカロテノイド;カルシフェロール及びアスコルビン酸から成る群から選択される、請求項1に記載の組成物。
  8. 1又は複数の電子伝達剤の1又は複数のリン酸誘導体の1又は複数の錯体における電子伝達剤が、トコフェリルホスフェート;アスコルビルホスフェート;P:トコフェリルP:アスコルビルホスフェートジエステル、トコトリエノールホスフェート;ユビキニルホスフェート、レチニルホスフェート;及びそれらの混合物、から成る群から選択される、請求項7に記載の組成物。
  9. 1又は複数の電子伝達剤の1又は複数のリン酸誘導体の錯体が、
    (a)アスコルビルホスフェート、レチニルホスフェート、トコフェリルホスフェート、トコトリエノールホスフェート及びP:トコフェリルP:アスコルビルホスフェートジエステル;ユビキニルホスフェート又はそれらの混合物から成る群から選択される電子伝達剤のリン酸塩と、
    (b)アルギニン、ヒスタジン及び第三級置換アミン、例えば以下の式:
    NR 1 R 2 R 3
    (ここで、R 1 はC6〜C22の直鎖又は分枝鎖の混合アルキル遊離基及びそれらのカルボニル誘導体を含んで成る群から選択され;
    R 2 及びR 3 は、H, CH 2 COOX, CH 2 CHOHCH 2 SO 3 X, CH 2 CHOHCH 2 OPO 3 X, CH 2 CH 2 COOX, CH 2 COOX, CH 2 CH 2 CHOHCH 2 SO 3 X又はCH 2 CH 2 CHOHCH 2 OPO 3 Xから成る群から独立して選択され、そしてXはH, Na, K又はアルカノールアミンであり、但しR 2 とR 3 は共にHであることはなく;そして
    ここで、R 1 がRCOである場合、R 2 はCH 3 であってもよく、且つR 3 は(CH 2 CH 2 )N(C 2 H 4 OH)-H 2 CHOPO 3 であってもよく、あるいはR 2 とR 3 は共にN(CH 2 ) 2 N(C 2 H 4 OH)CH 2 COO-であってもよい)に従うものとの反応産物から成る群から選択される、請求項1に記載の組成物。
  10. 抗生物質、抗ヒスタミン剤、殺菌剤、抗菌剤、サリチル酸、ビタミンA誘導体、抗炎症剤、角質分解剤、日焼け止め、及びそれらの混合物から成る群から選択される少なくとも1つのほかの活性成分を更に含んで成る、請求項1に記載の組成物。
  11. 抗生物質が、エリスロマイシン、リンコマイシンファミリー、セファロスポリン、テトラサイクリンファミリー、及びそれらの組み合わせから成る群から選択され、且つ全組成物の重量当たり0.01〜5.0%の量で存在する、請求項10に記載の組成物。
  12. (a)全組成物の重量当たり1〜10%のラウリルイミノジプロピオン酸トコフェリルホスフェート;
    (b)全組成物の重量当たり0.1〜10%のCarbomer Ultez 3%;
    (c)全組成物の重量当たり0.1〜10%のトリエタノールアミン;
    (d)任意の着色剤及び防腐剤;並びに
    (e)全組成物のバランス用の水、
    を含んで成る、請求項1に記載の組成物。
  13. 約3%(w/w)のラウリルイミノジプロピオン酸トコフェリルホスフェートを含んで成る、請求項12に記載の組成物。
  14. (a)全組成物の重量当たり0.1〜10%のラウリルイミノジプロピオン酸トコフェリルホスフェート;
    (b)全組成物の重量当たり0.1〜10%のグリセリン;
    (c)全組成物の重量当たり0.01〜5%のEDTA三ナトリウム;
    (d)全組成物の重量当たり0.01〜5%のカルボマー(Carbopol Ultez 10);
    (e)全組成物の重量当たり0.1〜10%のセテアリルアルコール(及び)Ceteareth-20(Phoenoxol T);
    (f)全組成物の重量当たり0.1〜5%のグリセリルステアラート;
    (g)全組成物の重量当たり0.1〜10%のイソプロピルミリステート;
    (h)全組成物の重量当たり0.1〜10%のセチルエチルヘキサノエート;
    (i)全組成物の重量当たり0.1〜10%のイソセチルベヘナート;
    (j)全組成物の重量当たり0.1〜10%のオレイルエルカート(oleyl erucate);
    (k)全組成物の重量当たり0.01〜5%のジメチコン;
    (l)全組成物の重量当たり0.01〜5%のトリエタノールアミン;
    (m)全組成物の重量当たり0.1〜10%のプロピレングリコール、ジアゾリジニルウレア、メチルパラベン、及びプロピルパラベン(Germaben ll);並びに
    (n)全組成物のバランス用の水、
    を含んで成る、請求項3に記載の組成物。
  15. 対象者の皮膚の症候を予防し、緩和し、又は皮膚の状態を処置するための薬剤の製造における、有効な皮膚浸透量の、1又は複数の電子伝達剤の1又は複数のリン酸誘導体の1又は複数の錯体と、局所的に許容される担体の使用。
  16. 皮膚の症候を予防し、緩和し、又は皮膚の状態を処置するための化粧用又は医薬用局所組成物であって、有効な皮膚浸透量の、1又は複数の電子伝達剤の1又は複数のリン酸誘導体を含んで成る化粧用又は医薬用局所組成物
  17. 局所的に許容される担体を更に含んで成る、請求項16に記載の組成物。
  18. 1又は複数の電子伝達剤の前記リン酸誘導体が、トコフェリルホスフェート;アスコルビルホスフェート;P:トコフェリルP:アスコルビルホスフェートジエステル、ユビキニルホスフェート;レチニルホスフェート;及びそれらの混合物、から成る群から選択される、請求項16に記載の組成物。
  19. 1又は複数の電子伝達剤の前記リン酸誘導体が、トコフェリルホスフェートのアルキルアミンホスファチジル誘導体である、請求項16に記載の組成物
  20. 対象者の皮膚の症候を予防し、緩和し、又は皮膚の状態を処置するための薬剤の製造における、有効な皮膚浸透量の、1又は複数の電子伝達剤の1又は複数のリン酸誘導体と、局所的に許容される担体との使用。
JP2003516533A 2001-07-27 2002-07-26 電子伝達剤のリン酸誘導体を用いた皮膚治療 Expired - Lifetime JP4745608B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30849601P 2001-07-27 2001-07-27
US30850601P 2001-07-27 2001-07-27
US60/308,506 2001-07-27
US60/308,496 2001-07-27
PCT/AU2002/001003 WO2003011303A1 (en) 2001-07-27 2002-07-26 Dermal therapy using phosphate derivatives of electron transfer agents

Publications (3)

Publication Number Publication Date
JP2004538308A JP2004538308A (ja) 2004-12-24
JP2004538308A5 true JP2004538308A5 (ja) 2006-01-05
JP4745608B2 JP4745608B2 (ja) 2011-08-10

Family

ID=26976276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003516533A Expired - Lifetime JP4745608B2 (ja) 2001-07-27 2002-07-26 電子伝達剤のリン酸誘導体を用いた皮膚治療

Country Status (9)

Country Link
US (1) US8008345B2 (ja)
EP (1) EP1420797A4 (ja)
JP (1) JP4745608B2 (ja)
CN (1) CN1547475B (ja)
AU (1) AU2002317053B2 (ja)
BR (1) BR0211673A (ja)
CA (1) CA2453823C (ja)
MX (1) MXPA04000654A (ja)
WO (1) WO2003011303A1 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
DE60140141D1 (de) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
DE60238276D1 (de) * 2001-12-13 2010-12-23 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
KR20050086954A (ko) * 2003-01-17 2005-08-30 바이탈 헬스 사이언시즈 피티와이 리미티드 항증식성 화합물
DE10307389A1 (de) * 2003-02-21 2004-09-02 Cognis Deutschland Gmbh & Co. Kg Anti-Aknemittel
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
JP2005053785A (ja) * 2003-05-20 2005-03-03 Nippon Menaade Keshohin Kk 外用剤
WO2005084678A1 (en) * 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
KR101238703B1 (ko) * 2004-08-03 2013-03-04 바이탈 헬스 사이언시즈 피티와이 리미티드 경구 투여용 담체
EP1858508A4 (en) * 2005-03-03 2009-01-07 Vital Health Sciences Pty Ltd COMPOUNDS HAVING ANTICANCER PROPERTIES
ES2557475T3 (es) * 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
AU2006257714B2 (en) * 2005-06-17 2011-07-21 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
KR20080085839A (ko) * 2005-12-23 2008-09-24 바이탈 헬스 사이언시즈 피티와이 리미티드 사이토킨 조절 특성을 가진 화합물
JP2008007428A (ja) * 2006-06-27 2008-01-17 Showa Denko Kk 皮膚外用シワ防止剤
NL1035426C2 (nl) * 2008-05-15 2009-11-17 Atp Marketing & Promotion Ag Farmaceutische samenstellingen voor de behandeling van wratten.
AU2010336018B2 (en) * 2009-12-23 2015-10-01 Phosphagenics Limited Carrier composition
SG182836A1 (en) * 2010-02-05 2012-09-27 Phosphagenics Ltd Carrier composition
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
FR2969924B1 (fr) * 2010-12-30 2013-11-15 Lvmh Rech Composition comprenant un phosphate de tocopherol
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINO-QUINOLINES AS KINASE INHIBITORS
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
DE102015217307A1 (de) 2015-09-10 2017-03-16 Bayerische Motoren Werke Aktiengesellschaft System zum Laden von Energiespeicherelementen von Elektrofahrzeugen
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
CN110662733A (zh) * 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
CN109172518B (zh) 2018-11-07 2019-12-13 扬子江药业集团上海海尼药业有限公司 一种含维生素k1的外用制剂及其制备方法
WO2022155656A1 (en) 2021-01-13 2022-07-21 Rodan & Fields, Llc Cosmetic compositions

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407823A (en) 1946-09-17 Antihemorrhagic esters and methods
US2667479A (en) 1951-01-30 1954-01-26 Merck & Co Inc Benzimidazole phosphate
GB778142A (en) 1953-11-20 1957-07-03 Leo Ab High-molecular weight derivatives of hydroxyl group-containing steroids and a method of producing them
US2913477A (en) 1957-03-22 1959-11-17 Merck & Co Inc Antihemorrhagic compounds and processes for preparing the same
US3127434A (en) 1959-10-20 1964-03-31 Hoffmann La Roche Dihydrovitamin k monophosphate compounds and preparation thereof
US3212901A (en) 1961-06-07 1965-10-19 Eastman Kodak Co Stabilized tocopherol concentrates and process for preparing the same
US3331896A (en) 1964-09-15 1967-07-18 Gen Aniline & Film Corp Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds
DE2526938C2 (de) 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
US4141938A (en) 1976-10-07 1979-02-27 Hoechst Aktiengesellschaft Production of acid orthophosphoric acid ester mixtures
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
US4299906A (en) 1979-06-01 1981-11-10 American Hoechst Corporation Light-sensitive color proofing film with surfactant in a light-sensitive coating
SU925961A1 (ru) 1980-08-15 1982-05-07 Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности Способ получени фосфорилированных глицеридов высших жирных кислот
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IT1157269B (it) 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
CH661438A5 (it) 1984-04-09 1987-07-31 Seuref Ag Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
US4603142A (en) 1984-06-01 1986-07-29 Wisconsin Alumni Research Foundation Cholesterol lowering method of use
EP0171009B1 (en) 1984-08-02 1991-05-22 HENKEL CORPORATION (a Delaware corp.) Purification of tocopherols by extraction
JPS6191137A (ja) 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
JPH0781138B2 (ja) 1986-12-02 1995-08-30 株式会社資生堂 抗酸化剤
DE3702766A1 (de) 1987-01-30 1988-08-11 Henkel Kgaa Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern
JP3070744B2 (ja) 1987-04-10 2000-07-31 株式会社日立製作所 ベクトル処理装置
US4952495A (en) 1987-06-08 1990-08-28 Eastman Kodak Company Hydrolyzable compounds which release electron transfer agents and analytical use of same
PH25859A (en) 1988-01-11 1991-12-02 Takeda Chemical Industries Ltd Composition for treatment of ischemic disorder
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE3813624A1 (de) 1988-04-22 1989-11-02 Basf Ag Verfahren zur herstellung von d-(alpha)-tocopherol aus natuerlichen vorprodukten
CA2007643A1 (en) 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
US6028105A (en) * 1989-04-06 2000-02-22 Nigra; Thomas P. Topical drug delivery composition and method
US5053222A (en) 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
DE3927113C2 (de) 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
JP2854631B2 (ja) 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
IT1236843B (it) 1989-11-22 1993-04-21 Simes Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati
JPH03206089A (ja) 1990-01-05 1991-09-09 Eisai Co Ltd 新規ビタミンe誘導体及びその製造方法
US5374645A (en) 1990-01-22 1994-12-20 Ciba-Geigy Corporation Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
JP3035742B2 (ja) * 1990-11-30 2000-04-24 昭和電工株式会社 化粧品
FR2679904A1 (fr) * 1991-08-01 1993-02-05 Lvmh Rech Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues.
US5643597A (en) 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
EP0535283A1 (en) 1991-10-02 1993-04-07 Merrell Dow Pharmaceuticals Inc. Cardioprotective tocopherol analogs
US5474891A (en) 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
EP0543417A1 (en) 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US5282312A (en) 1991-12-31 1994-02-01 Tessera, Inc. Multi-layer circuit construction methods with customization features
JPH05286848A (ja) 1992-04-10 1993-11-02 Senju Pharmaceut Co Ltd 浴用剤
GB9212450D0 (en) 1992-06-11 1992-07-22 Indena Spa New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them
US5741518A (en) 1992-08-03 1998-04-21 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5348357A (en) 1992-12-24 1994-09-20 General Motors Corporation Vehicle closure latch having plastic coated ratchet
US6384043B1 (en) 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
TW252918B (ja) 1993-03-31 1995-08-01 Senju Pharma Co
GB9318271D0 (en) 1993-09-03 1993-10-20 Scotia Holdings Plc Tocopherols
CA2129509A1 (en) 1993-09-10 1995-03-11 Kazumi Ogata Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis
EP0730439A1 (en) 1993-11-27 1996-09-11 Knoll AG Compositions comprising iminium ion scavengers and/or nitrite scavengers
JPH07196516A (ja) 1993-12-29 1995-08-01 Senju Pharmaceut Co Ltd 痔疾患治療剤
JPH07207298A (ja) * 1994-01-21 1995-08-08 Nippon Oil & Fats Co Ltd 洗浄剤組成物
FR2715565B1 (fr) 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
EP0669132A1 (en) 1994-02-23 1995-08-30 van der Kraaij, Antonius Marinus Maria Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis
CA2145229A1 (en) 1994-03-29 1995-09-30 Tetsuya Toge Suppressory compositions against hepatic metastases of tumors
US5554781A (en) 1994-03-30 1996-09-10 Reierson; Robert L. Monoalkyl phosphonic acid ester production process
JPH07277988A (ja) 1994-04-05 1995-10-24 Senju Pharmaceut Co Ltd 局所用掻痒除去、治療剤
TW287103B (ja) * 1994-04-22 1996-10-01 Senju Pharma Co
JP3362501B2 (ja) 1994-04-28 2003-01-07 千寿製薬株式会社 角膜障害治療剤
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5589504A (en) 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
CA2152693A1 (en) 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH0873338A (ja) * 1994-09-02 1996-03-19 Noevir Co Ltd 皮膚外用剤
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
FR2730928B1 (fr) 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
KR100387156B1 (ko) 1995-04-21 2003-10-11 세키스이가가쿠 고교가부시키가이샤 피부질환치료용외용제
JPH08311489A (ja) * 1995-05-19 1996-11-26 Nippon Oil & Fats Co Ltd 洗浄剤組成物
JP3622267B2 (ja) * 1995-05-31 2005-02-23 日本油脂株式会社 洗浄剤組成物
US5607968A (en) * 1995-06-07 1997-03-04 Avon Products, Inc. Topical alkyl-2-O-L-ascorbyl-phosphates
EP0780116B1 (en) * 1995-07-12 2002-09-25 Shiseido Company Limited External skin preparation
US5965750A (en) 1995-10-17 1999-10-12 Showa Denko K.K. High- purity tocopherol phosphates, process for the preparation thereof, methods for analysis thereof, and cosmetics
FR2741263B1 (fr) 1995-11-22 1997-12-26 Oreal Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique
DE69736468T2 (de) 1996-03-27 2007-03-29 Inspire Pharmaceuticals, Inc. Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5885595A (en) 1996-05-13 1999-03-23 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic composition with a retinol fatty acid ester
JPH09309813A (ja) * 1996-05-22 1997-12-02 Nonogawa Shoji Kk 皮膚外用剤
CA2209690A1 (en) 1996-07-31 1998-01-31 Sachiko Matsuura Therapeutic drug for acne vulgaris
JPH1067639A (ja) 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンe−ビタミンcリン酸ジエステル/シクロデキストリン包接物及び該包接物を配合した皮膚外用剤
US6022867A (en) 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
JPH10155429A (ja) 1996-11-27 1998-06-16 Showa Denko Kk 動物に対するビタミンe供給方法および動物用トコフェロールリン酸エステル又はその塩類組成物
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
DE69840622D1 (de) 1997-01-29 2009-04-16 Kao Corp Kosmetikprodukt
KR100563764B1 (ko) 1997-03-13 2006-03-24 헥살 아게 아미노산과 시클로덱스트린과의 병용에 의한 산(酸) 민감성 벤즈이미다졸류의 안정화 방법
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
JP2926046B2 (ja) * 1997-06-04 1999-07-28 株式会社太平洋 水安定型l−アスコルビン酸誘導体とその製造方法及びこれを含有する美白化粧料組成物
US5928631A (en) * 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5776915A (en) 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
US6096326A (en) * 1997-08-15 2000-08-01 Scandinavian-American Import/Export Corporation Skin care compositions and use
JPH11199465A (ja) * 1998-01-07 1999-07-27 Nonogawa Shoji Kk 皮膚外用剤
WO1999039716A1 (fr) 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Substances preventives et medicaments destines aux maladies neurodegeneratives
US6461623B2 (en) * 1998-04-13 2002-10-08 Kao Corporation Cosmetic composition
JP4208209B2 (ja) 1998-06-22 2009-01-14 フジノン株式会社 コリメータレンズおよびこれを用いた光走査装置
US6121249A (en) 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
CA2336682C (en) 1998-07-07 2006-10-10 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
CA2345079C (en) 1998-09-23 2011-06-21 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
AUPQ037499A0 (en) 1999-05-14 1999-06-10 Swig Pty Ltd Improved process for phosphorylation and compounds produced by this method
AUPP829399A0 (en) 1999-01-25 1999-02-18 Swig Pty Ltd Recovery for chroman derivatives
JP2000212082A (ja) * 1999-01-26 2000-08-02 Showa Denko Kk 皮膚用剤
US6156354A (en) 1999-01-29 2000-12-05 Brandeis University Hyper-absorption of vitamin E dispersed in milks
US6184247B1 (en) * 1999-05-21 2001-02-06 Amway Corporation Method of increasing cell renewal rate
AU5594700A (en) 1999-06-01 2000-12-18 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2001015593A2 (en) 1999-09-02 2001-03-08 Drake Larson Compositions for reducing vascular plaque formation and methods of using same
JP2003513019A (ja) 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス,インコーポレイテッド トコール可溶性治療剤の組成物
NZ520798A (en) 2000-02-11 2004-05-28 Res Dev Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6635253B2 (en) 2000-02-29 2003-10-21 Showa Denko Kabushiki Kaisha Composition for enhancing immunological effects
US6346544B2 (en) 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
JP2001247585A (ja) 2000-03-03 2001-09-11 Nof Corp トコフェロール誘導体、その中間体、その製造方法及び用途
US6444220B2 (en) 2000-03-16 2002-09-03 Teresa S. Wiley Method and compositions for changing the contour of skin
US6361800B1 (en) 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
KR100365070B1 (ko) 2000-08-29 2002-12-16 주식회사 태평양 토코페롤 유도체 및 그의 제조방법
JP4818500B2 (ja) 2000-09-05 2011-11-16 株式会社ペンタプラストア トコトリエノール誘導体及びその製造方法
US20030206972A1 (en) 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
CA2426852C (en) 2000-11-14 2010-01-26 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
DE60140141D1 (de) 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
CA2430415A1 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
US20020131994A1 (en) 2001-01-10 2002-09-19 Schur Henry B. Non-irritating formulation for the transdermal delivery of substances
US6849271B2 (en) 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
KR100394770B1 (ko) 2001-06-05 2003-08-14 주식회사 태평양 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물
AUPR684801A0 (en) 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
AU2002951045A0 (en) 2002-08-27 2002-09-12 Vital Health Sciences Pty Ltd Method of supplementing nascent endogenous storage forms
JP2003128531A (ja) 2001-10-17 2003-05-08 Nonogawa Shoji Kk 皮膚外用剤
DE60238276D1 (de) 2001-12-13 2010-12-23 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040067890A1 (en) 2002-10-04 2004-04-08 Gupta Shyam K. Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions
US6645514B1 (en) 2002-12-19 2003-11-11 Access Business Group International, Llc Increasing skin cell renewal with water-soluble Vitamin E
KR20050086954A (ko) 2003-01-17 2005-08-30 바이탈 헬스 사이언시즈 피티와이 리미티드 항증식성 화합물
US7033998B2 (en) 2003-04-11 2006-04-25 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
AU2003901813A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
AU2003901812A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphates of secondary alcohols
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
WO2005084678A1 (en) 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
KR101238703B1 (ko) 2004-08-03 2013-03-04 바이탈 헬스 사이언시즈 피티와이 리미티드 경구 투여용 담체
US20090239827A1 (en) 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
EP1858508A4 (en) 2005-03-03 2009-01-07 Vital Health Sciences Pty Ltd COMPOUNDS HAVING ANTICANCER PROPERTIES
JP4270212B2 (ja) 2005-03-29 2009-05-27 セイコーエプソン株式会社 基板間隔調整装置、基板間隔調整方法、および液晶表示装置の製造方法
ES2557475T3 (es) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
KR20080085839A (ko) 2005-12-23 2008-09-24 바이탈 헬스 사이언시즈 피티와이 리미티드 사이토킨 조절 특성을 가진 화합물

Similar Documents

Publication Publication Date Title
JP2004538308A5 (ja)
CA2453823A1 (en) Dermal therapy using phosphate derivatives of electron transfer agents
DE3690187C2 (de) Naphthalinderivate mit retinoider Wirkung, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische und kosmetische Mittel
EP0578077B1 (en) Compositions containing retinoic acids and tocopherol
US8921423B2 (en) Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
CA2316349C (en) Compositions and method for protecting skin from uv induced immunosuppression and skin damage
EP0787005B1 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
CA2495280A1 (en) Topical pharmaceutical carrier
ES2703505T3 (es) Combinación de adapaleno y peróxido de benzoilo para tratar lesiones de acné
WO1995026180A1 (de) Hautpflegemittel
JP2011516483A5 (ja)
EP0229654B1 (en) Treatment of non-acne inflammatory and infectious dermatoses
ES2316312A1 (es) Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
JP2016515525A5 (ja)
RU2125554C1 (ru) Би-ароматические ацетиленовые соединения с группой адамантила, фармацевтическая и косметическая композиции на их основе
RU2015103469A (ru) Ретиноиды и их применение
EP1147086B1 (en) Compositions for the treatment of skin diseases
CA2209690A1 (en) Therapeutic drug for acne vulgaris
US8673356B2 (en) Stable fixed dose topical formulation
CA1241919A (en) Non-steroidal anti-inflammatory compounds and compositions thereof
US9375477B2 (en) Topical compositions of aqueous gel type in the form of a homogeneous suspension of an active principle of the retinoid class containing at least one hydrophobic silica
US20070248555A1 (en) Composition and method for managing redness of skin associated with dermatological condition
MX2014006051A (es) Uso de alcoholes pegilados para el tratamiento de queratosis actinica.
DE69801353T2 (de) Ungesättigte in 4-Stellung substituierte 6-tert-Butyl-1,-Dimethylindan-Derivate und deren Verwendung in der Human- und Veterinärmedizin
WO1983000628A1 (en) A method of treating acne vulgaris and composition containing carbamide peroxide